Posted by Michael Wonder on 23 May 2022
US FDA accepts for review Biohaven's new drug application filing of intranasal zavegepant for the acute treatment of migraine
23 May 2022 - If approved, zavegepant nasal spray would be the only FDA approved calcitonin gene related peptide receptor antagonist in an intranasal formulation, giving patients a new treatment option that provides ultra-rapid pain relief in as little as 15 minutes that lasts through 48 hours after a single dose.
Biohaven Pharmaceutical today announced that the U.S. FDA has filed and accepted for review a new drug application for zavegepant nasal spray, the only small molecule calcitonin gene related peptide receptor antagonist in an intranasal formulation, for the acute treatment of migraine in adults.
